Bright Minds Biosciences ...

35.34
-1.90 (-5.10%)
At close: Mar 03, 2025, 3:59 PM
34.92
-1.18%
After-hours: Mar 03, 2025, 04:00 PM EST

Company Description

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases.

Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.

The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.

The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. logo
Country CA
IPO Date Mar 22, 2021
Industry Biotechnology
Sector Healthcare
Employees n/a
CEO Ian McDonald

Contact Details

Address:
1500 – 1055 West Georgia Street
Vancouver, BC
CA
Website https://brightmindsbio.com

Stock Details

Ticker Symbol DRUG
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001827401
CUSIP Number 10919W108
ISIN Number CA10919W4056
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Ian McDonald Co-Founder, Chief Executive Officer, President & Director
Alex Vasilkevich Chief Operating Officer & Vice President of Corporate Development
Ryan E. S. K. Cheung B.Com., CA, CPA Chief Financial Officer
Dr. Emer Leahy M.B.A., Ph.D. Consultant
Dr. Jan Torleif Pedersen M.Sc., Ph.D. Chief Science Officer & Director
Dr. Stephen D. Collins M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 24, 2025 6-K Filing
Feb 14, 2025 424B3 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 6-K Filing
Feb 10, 2025 SCHEDULE 13G Filing
Feb 07, 2025 SCHEDULE 13G Filing
Feb 05, 2025 F-3 Filing